Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKinsey
Baxter
Medtronic
Merck

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Cefepime Hydrochloride In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00020865 ↗ Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status National Cancer Institute (NCI) Phase 3 2001-09-01 RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer.
NCT00020865 ↗ Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status Jonsson Comprehensive Cancer Center Phase 3 2001-09-01 RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer.
NCT00044759 ↗ Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 1969-12-31 To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
NCT00137787 ↗ Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases Completed Bayer Phase 3 2005-04-01 The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.
NCT00137787 ↗ Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases Completed Center for Supporting Hematology-Oncology Trials Phase 3 2005-04-01 The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cefepime Hydrochloride In Plastic Container

Condition Name

Condition Name for Cefepime Hydrochloride In Plastic Container
Intervention Trials
Febrile Neutropenia 4
Leukemia 3
Healthy Subjects 3
Neutropenia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cefepime Hydrochloride In Plastic Container
Intervention Trials
Infections 15
Infection 14
Communicable Diseases 13
Neutropenia 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cefepime Hydrochloride In Plastic Container

Trials by Country

Trials by Country for Cefepime Hydrochloride In Plastic Container
Location Trials
United States 70
Spain 9
India 8
Poland 7
Brazil 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cefepime Hydrochloride In Plastic Container
Location Trials
Texas 9
California 7
Florida 5
New York 5
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cefepime Hydrochloride In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Cefepime Hydrochloride In Plastic Container
Clinical Trial Phase Trials
Phase 4 12
Phase 3 17
Phase 2/Phase 3 1
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cefepime Hydrochloride In Plastic Container
Clinical Trial Phase Trials
Completed 26
Terminated 8
Not yet recruiting 6
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cefepime Hydrochloride In Plastic Container

Sponsor Name

Sponsor Name for Cefepime Hydrochloride In Plastic Container
Sponsor Trials
Wockhardt 6
M.D. Anderson Cancer Center 5
National Cancer Institute (NCI) 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cefepime Hydrochloride In Plastic Container
Sponsor Trials
Other 58
Industry 31
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Colorcon
McKesson
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.